CollPlant Biotechnologies
CLGN
3 hedge funds and large institutions have $625K invested in CollPlant Biotechnologies in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
412% more capital invested
Capital invested by funds: $122K → $625K (+$503K)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
50% more funds holding
Funds holding: 2 → 3 (+1)
0.07% more ownership
Funds ownership: 0.01% → 0.08% (+0.07%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
+$739K |
| 2 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
+$21.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$72K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$34K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MIH
1
Meitav Investment House
Bene-Beraq,
Israel
| $594K | +$739K | +141,662 | New |
|
|
HIIFS
2
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
| $17K | +$21.4K | +4,106 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| $14K | -$34K | -6,515 | -66% |
|
|
4
Citadel Advisors
Miami,
Florida
| – | -$72K | -13,885 | Closed |
|
CLGN Hedge Fund Activity: Q4 2018 in Review
3 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in CollPlant Biotechnologies (CLGN) for Q4 2018, worth a combined $625K — up 412% from $122K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new CLGN positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Meitav Investment House, opening a new position worth an estimated $739K. The largest seller was Citadel Advisors, exiting entirely with an estimated $72K sold.
- 3 institutional investors held CollPlant Biotechnologies (CLGN) as of Q4 2018, up from 2 in Q3 2018.
- Funds reported $625K of CollPlant Biotechnologies stock for Q4 2018, up 412% quarter-over-quarter.
- 2 funds opened new CollPlant Biotechnologies positions in Q4 2018 and 1 closed out, a net change of +1 holder.
- The largest CollPlant Biotechnologies buyer in Q4 2018 was Meitav Investment House, an estimated $739K added.
- The largest CollPlant Biotechnologies seller in Q4 2018 was Citadel Advisors, an estimated $72K sold.
Based on aggregated 13F filings for Q4 2018.